Markets:

Overview

News

Currencies

International

Treasuries

Sierra Oncology, Inc. - Common Stock (NQ:SRRA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sierra Oncology, Inc. - Common Stock

< Previous 1 2 3 Next >

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗

June 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

June 17, 2022

From Sierra Oncology

Via Business Wire

6 Biotech Stocks to Buy Now Ahead of These June Catalysts ↗

June 03, 2022

These biotech stocks face some key make-or-break events in June that could have big implication for their futures.

Via InvestorPlace

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

Recap: Sierra Oncology Q1 Earnings ↗

May 06, 2022

Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Sierra Oncology ↗

April 14, 2022

Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

May 26, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

May 12, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Reports First Quarter 2022 Results

May 06, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 05, 2022

From Sierra Oncology

Via Business Wire

SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

May 02, 2022

From Kuznicki Law PLLC

Via Business Wire

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

April 25, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗

April 17, 2022

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗

April 14, 2022

Upgrades

Via Benzinga

Analyzing Sierra Oncology Inc's Short Interest ↗

April 14, 2022

Sierra Oncology Inc's (NASDAQ:SRRA) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 1.21 million shares sold short, which...

Via Benzinga

Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

April 14, 2022

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

Via FinancialNewsMedia

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 13, 2022

Gainers

Via Benzinga

Why Is Creatd (CRTD) Stock Up Today? ↗

April 13, 2022

Creatd (CRTD) stock is heading higher on Wednesday following news of a deal for wellness beverage subsidiary Dune Glow Remedy.

Via InvestorPlace

Dear KLDO Stock Fans, Mark Your Calendars for April 28 ↗

April 13, 2022

Kaleido Biosciences (KLDO) stock is soaring on Wednesday but anyone considering a stake in the company will want to keep an eye on April 28.

Via InvestorPlace

Why Is Sierra Oncology (SRRA) Stock Up Today? ↗

April 13, 2022

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

Via InvestorPlace

Sierra Oncology Stock Is Soaring: Here's Why ↗

April 13, 2022

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022 ↗

April 13, 2022

Upgrades

Via Benzinga

Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗

April 13, 2022

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Via Investor's Business Daily

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders

April 13, 2022

From Halper Sadeh LLP

Via Business Wire

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal ↗

April 13, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

April 13, 2022

Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

April 13, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 06, 2022

From Sierra Oncology

Via Business Wire

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.